Iovance Biotherapeutics
IOVA
80 hedge funds and large institutions have $199M invested in Iovance Biotherapeutics in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 16 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 18
8% less call options, than puts
Call options by funds: $495K | Put options by funds: $538K
7% less funds holding
Funds holding: 86 → 80 (-6)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less capital invested
Capital invested by funds: $325M → $199M (-$127M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
+$5.22M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.34M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$2.82M |
| 4 |
BC
Broadfin Capital
New York
|
+$2.28M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$6.96M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$2.31M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.97M |
| 4 |
PP
PDT Partners
New York
|
-$631K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$585K |
IOVA Hedge Fund Activity: Q3 2015 in Review
80 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2015, worth a combined $199M — down 39% from $325M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of IOVA and 11 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 36 added.
The largest buyer was RS Investment Management, adding an estimated $5.22M. The largest seller was Tourbillon Capital Partners, exiting entirely with an estimated $6.96M sold.
- 80 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2015, down from 86 in Q2 2015.
- Funds reported $199M of Iovance Biotherapeutics stock for Q3 2015, down 39% quarter-over-quarter.
- 11 funds opened new Iovance Biotherapeutics positions in Q3 2015 and 16 closed out, a net change of -5 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2015 was RS Investment Management, an estimated $5.22M added.
- The largest Iovance Biotherapeutics seller in Q3 2015 was Tourbillon Capital Partners, an estimated $6.96M sold.
Based on aggregated 13F filings for Q3 2015.